Developer docs
API playgroundTry for free, no card

Search company profiles

Egis Pharmaceuticals

Full company profile

uuid0008y38

Namestring
Egis Pharmaceuticals
Legal namestring
Egis Gyógyszergyár Zártkörűen Működő Részvénytársaság
Websiteurl
hu.egis.health
Company typeenum
Private
Founded yearint
1913
Descriptiontext

Egis Pharmaceuticals PLC (legal name: Egis Gyógyszergyár Zártkörűen Működő Részvénytársaság) is a Hungarian pharmaceutical manufacturer founded in 1913 from the predecessor Dr. Wander Gyógyszer- és Tápszergyár, headquartered in Budapest with manufacturing operations across two Budapest sites and one in Körmend. The company is a privately held subsidiary of France's Servier Group and ranks as Hungary's 29th-largest employer. Egis operates a fully vertically integrated pharmaceutical value chain spanning R&D, active pharmaceutical ingredient (API) development and manufacturing, finished dosage form production (tablets, injections, ointments, suppositories, syrups), packaging, and sales across cardiovascular, central nervous system, diabetology, dermatology, gastroenterology, oncology, and women's health therapeutic areas. Its portfolio comprises 653 products across 177 product families derived from 158 active ingredients.

The company's manufacturing technology is built around cGMP-compliant organic chemical synthesis spanning more than 30 reaction types — including catalytic hydrogenation, Grignard, Friedel-Crafts, Mannich, asymmetric hydrogenation, and chiral resolution — using reactor scales from 630L to 10,000L and specialized equipment such as tantalum-coated reactors and short path three-stage distillation. A distinctive capability is highly potent (HP) API handling at OEB4 (OEL < 10 μg) in transparent closed isolators with a dedicated GMP production line providing approximately 600 kg of annual capacity. Facilities hold accreditations from FDA (since 1976), EDQM, PMDA, KFDA, and ANVISA, and comply with ICH Q7, Q11, Q2(R1), Q1A(R2), Q3D, and M7 guidelines — collectively enabling market access across the US, EU, Japan, South Korea, and Brazil.

Egis makes money through three revenue streams: sale of in-house generic pharmaceutical products, licensing of products and technologies to partners, and — since 2023 — contract development and manufacturing services (CDMO) for pharmaceutical partners globally, marketed as Egis Pharma Services. Distribution reaches 100 countries via 17 wholly-owned subsidiaries (including in Poland, Russia, the Baltic states, CIS, Caucasus, and Vietnam) and partner networks in remaining markets. End customers are healthcare professionals and pharmacies; CDMO clients are pharmaceutical companies requiring cGMP-compliant API development and manufacturing support.

Short descriptiontext

Egis Pharmaceuticals is a 110-year-old Hungarian vertically integrated generic pharmaceutical manufacturer, producing 653 products across 158 active ingredients and selling to pharmacies, physicians, and pharmaceutical partners in 100 countries under the Servier Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBudapest, Hungary
HQ citystring
Budapest
HQ countrystring
Hungary
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, active pharmaceutical ingredients, pharmaceutical contract manufacturing, finished dosage forms, over-the-counter medicines
Industry3 codes
PRIMARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYCRAOAHAB
OTC Medicines & Consumer Health Products Distribution
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Pharmaceutical Products
TypeOne Time License
Description

Sale of generic pharmaceutical products manufactured in-house. Portfolio of 653 products across 177 product families from 158 active ingredients. Products include cardiovascular, CNS, and other therapeutic categories sold in 100 countries.

hu.egis.health
2Contract Manufacturing Services
TypeProfessional Services
Description

API contract development and manufacturing services offered to pharmaceutical partners. Services include process development, scale-up, and commercial API production under cGMP. Started in 2023.

hu.egis.health
3Licensing Activities
TypeLicensing Royalties
Description

Licensing of pharmaceutical products and technologies to partners in various markets.

hu.egis.health
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Egis Pharma Services
Description

Contract manufacturing and contract development services for active pharmaceutical ingredients offered to pharmaceutical partners.

hu.egis.health
Core offering1 text field

Egis manufactures and distributes generic pharmaceutical products including active pharmaceutical ingredients (APIs) and finished dosage forms — tablets, injections, and galenic preparations (ointments, suppositories, solutions, syrups) — across cardiovascular, CNS, diabetes, dermatology, gastroenterology, oncology, and women's health therapeutic areas, as well as a portfolio of OTC consumer health products. The company operates the full pharmaceutical value chain from API development and manufacturing through finished product manufacturing, packaging, sales, marketing, and licensing, supported by FDA-, EDQM-, PMDA-, KFDA-, and ANVISA-accredited cGMP facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Products reach 100 countries globally
+3 more records
Product overview1 text field

Egis Pharmaceuticals is a pharmaceutical company with a comprehensive portfolio spanning active pharmaceutical ingredients (APIs) and finished dosage forms including tablets, injections, and galenic preparations (ointments, suppositories, solutions, syrups). The company manufactures 653 products organized into 177 product families derived from 158 different active ingredients, distributed to over 100 countries. Key therapeutic areas include cardiovascular (heart and vascular) and central nervous system, supplemented by diabetes, dermatology, and wound care. Egis also operates three Hungarian manufacturing sites (Budapest Keresztúri út for API production, Budapest Bökényföldi út for injectables and packaging, and Körmend for tablets and galenic products) and offers contract development and manufacturing services for pharmaceutical partners, including active ingredient development and manufacturing for both traditional and highly potent compounds.

Product and service14 records
1Pharmaceutical Products Portfolio
CategoryCore product
Description

Core portfolio of 653 generic pharmaceutical products across 177 product families derived from 158 active ingredients, including APIs and finished dosage forms (tablets, injections, galenic preparations such as ointments, suppositories, solutions, syrups), distributed to 100 countries. Intended for healthcare professionals, pharmacies, and patients in cardiovascular, CNS, diabetes, dermatology, gastroenterology, oncology, and women's health therapeutic areas.

2Cardiovascular Pharmaceuticals
CategoryTherapeutic product line
Description

Generic prescription pharmaceutical products for the cardiovascular therapeutic area (heart and vascular diseases), one of Egis's two primary focus areas in Hungary. Sold through pharmacies and via field sales representatives to physicians and pharmacists.

3Central Nervous System Pharmaceuticals
CategoryTherapeutic product line
Description

Generic prescription pharmaceutical products for central nervous system disorders (neurological and psychiatric conditions), one of Egis's two primary focus areas in Hungary. Sold through pharmacies and via field sales representatives.

4Crila (OTC anti-diarrhea)
CategoryOTC product
Description

Over-the-counter anti-diarrhea product available without prescription through Hungarian pharmacies.

5Reparon (OTC hemorrhoid treatment)
CategoryOTC product
Description

Over-the-counter hemorrhoid treatment available without prescription through Hungarian pharmacies.

6Betadine (OTC skin disinfection)
CategoryOTC product
Description

Over-the-counter skin disinfection product available through Hungarian pharmacies.

7Telviran (OTC herpes treatment)
CategoryOTC product
Description

Over-the-counter herpes treatment available through Hungarian pharmacies.

8Ambroxol Egis (OTC respiratory)
CategoryOTC product
Description

Over-the-counter respiratory medication for acute and chronic respiratory conditions with mucus secretion, available through Hungarian pharmacies.

9Paxirasol (OTC respiratory)
CategoryOTC product
Description

Over-the-counter respiratory product for cough, asthma, and bronchitis to help clear airways, available through Hungarian pharmacies.

10Egis Pharma Services
CategoryService offering
Description

Contract development and manufacturing services (CDMO) for active pharmaceutical ingredients (APIs) offered to pharmaceutical partners globally under cGMP, covering route scouting, synthesis development, scale-up, and commercial API production including highly potent compounds. Brand sub-brand of Egis.

11Active Ingredient Contract Development
CategoryService offering
Description

Contract development services for active pharmaceutical ingredients including both traditional and highly potent (HP) compounds, with Budapest facilities featuring isolators for safe handling under cGMP.

12Active Ingredient Contract Manufacturing
CategoryService offering
Description

Contract manufacturing of intermediates and active pharmaceutical ingredients using organic chemical synthesis with GMP-compliant processes at Budapest facilities, with reactor capacity from 630 L to 10,000 L.

13HP Drug Substance Development and Manufacturing
CategoryService offering
Description

Highly potent drug substance development and GMP manufacturing with OEL levels between 1-10 micrograms (OEB4), including synthesis development, scale-up, and isolated production; dedicated production line capacity ~600 kg/year.

14Chemical Manufacturing Services
CategoryService offering
Description

Large-scale chemical synthesis manufacturing services including aminolysis, Grignard reactions, nitration, hydrogenation, Friedel-Crafts reactions, and other specialized organic chemistry processes performed under cGMP.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Pharmaceutical Industry Partners (unspecified)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Pharmaceutical partners for whom Egis provides contract development and manufacturing services for active pharmaceutical ingredients. Services include route scouting, synthesis development, scale-up, and commercial API production under cGMP conditions.

hu.egis.health
2Regulatory Authorities (FDA, EDQM, PMDA, KFDA, ANVISA)
Strategic tierCoreTypeOthers
Description

Accreditation and audit relationships with major regulatory authorities worldwide. Successfully passed comprehensive audits and received accreditation from FDA (USA, first in 1976), EDQM (EU), PMDA (Japan), KFDA (South Korea), ANVISA (Brazil).

hu.egis.health
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Egis engages with healthcare professionals (physicians, pharmacists) for product promotion, clinical collaboration, and transparency reporting under EFPIA Transparency Code. Healthcare organizations receive support and attend company-organized events.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Iceland-based biosimilar-focused manufacturer with vertically integrated development and manufacturing capabilities. Comparable to Egis's higher-end API capabilities (HP, isolator, advanced chemistry) and as a potential adjacent competitor for sophisticated contract manufacturing opportunities.

2Recipharm
TypeDirect peer
Description

European CDMO offering contract development and manufacturing of APIs and finished dosage forms. Comparable to Egis's newly launched Egis Pharma Services API CDMO business, competing for the same pharmaceutical partner customers.

3Sandoz
TypeBroad incumbent
Description

Novartis's standalone generics and biosimilars division with European heritage and broad API and finished product operations. Comparable to Egis on European generics distribution and biosimilar/specialty optionality, though at materially larger scale.

TypeDirect peer
Description

German-headquartered European generics and consumer healthcare company with broad portfolio across cardiovascular, CNS, and OTC categories. Comparable to Egis as a European-focused, vertically organized generic and OTC manufacturer with multi-country distribution.

TypeDirect peer
Description

Slovenian generic pharmaceutical manufacturer with strong CEE/CIS distribution, vertically integrated API production, and broad therapeutic coverage. Highly comparable to Egis in scale, footprint, and generics-led business model.

TypeDirect peer
Description

Polish pharmaceutical manufacturer and one of the largest CEE generic producers, with vertically integrated API and finished product manufacturing. Comparable to Egis on regional scale, therapeutic breadth, and integrated generics model.

TypeBroad incumbent
Description

Multinational generic and specialty pharmaceutical manufacturer with strong MENA, US, and Europe presence. Comparable to Egis on vertically integrated generic manufacturing and broad geographic distribution, though with greater US exposure.

TypeDirect peer
Description

Hungarian-headquartered pharmaceutical company with vertically integrated generic and specialty pharma operations across CEE and Western Europe. Closely comparable to Egis on geography, therapeutic focus (CNS, cardiovascular, women's health), and integrated API-to-finished-product model.

TypeBroad incumbent
Description

Global generics and specialty pharma leader with extensive API and finished product operations. Comparable to Egis as a broader incumbent offering overlapping generic categories and contract manufacturing services, but at much larger scale.

TypeDirect peer
Description

Czech-headquartered European generic pharmaceutical company (formerly Sanofi generics) with strong CEE presence and broad finished-product portfolio. Comparable to Egis in CEE-centric generics focus and finished dosage-form manufacturing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance14 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Egis Pharmaceuticals

Generic Pharmaceuticalshu.egis.health

Egis Pharmaceuticals is a 110-year-old Hungarian vertically integrated generic pharmaceutical manufacturer, producing 653 products across 158 active ingredients and selling to pharmacies, physicians, and pharmaceutical partners in 100 countries under the Servier Group.

What Egis Pharmaceuticals does

Egis Pharmaceuticals PLC (legal name: Egis Gyógyszergyár Zártkörűen Működő Részvénytársaság) is a Hungarian pharmaceutical manufacturer founded in 1913 from the predecessor Dr. Wander Gyógyszer- és Tápszergyár, headquartered in Budapest with manufacturing operations across two Budapest sites and one in Körmend. The company is a privately held subsidiary of France's Servier Group and ranks as Hungary's 29th-largest employer. Egis operates a fully vertically integrated pharmaceutical value chain spanning R&D, active pharmaceutical ingredient (API) development and manufacturing, finished dosage form production (tablets, injections, ointments, suppositories, syrups), packaging, and sales across cardiovascular, central nervous system, diabetology, dermatology, gastroenterology, oncology, and women's health therapeutic areas. Its portfolio comprises 653 products across 177 product families derived from 158 active ingredients.

The company's manufacturing technology is built around cGMP-compliant organic chemical synthesis spanning more than 30 reaction types — including catalytic hydrogenation, Grignard, Friedel-Crafts, Mannich, asymmetric hydrogenation, and chiral resolution — using reactor scales from 630L to 10,000L and specialized equipment such as tantalum-coated reactors and short path three-stage distillation. A distinctive capability is highly potent (HP) API handling at OEB4 (OEL < 10 μg) in transparent closed isolators with a dedicated GMP production line providing approximately 600 kg of annual capacity. Facilities hold accreditations from FDA (since 1976), EDQM, PMDA, KFDA, and ANVISA, and comply with ICH Q7, Q11, Q2(R1), Q1A(R2), Q3D, and M7 guidelines — collectively enabling market access across the US, EU, Japan, South Korea, and Brazil.

Egis makes money through three revenue streams: sale of in-house generic pharmaceutical products, licensing of products and technologies to partners, and — since 2023 — contract development and manufacturing services (CDMO) for pharmaceutical partners globally, marketed as Egis Pharma Services. Distribution reaches 100 countries via 17 wholly-owned subsidiaries (including in Poland, Russia, the Baltic states, CIS, Caucasus, and Vietnam) and partner networks in remaining markets. End customers are healthcare professionals and pharmacies; CDMO clients are pharmaceutical companies requiring cGMP-compliant API development and manufacturing support.

Egis Pharmaceuticals firmographics

Firmographics
Name
Egis Pharmaceuticals
Legal name
Egis Gyógyszergyár Zártkörűen Működő Részvénytársaság
Website
https://hu.egis.health
Company type
Private
Founded year
1913
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Egis Pharmaceuticals is a 110-year-old Hungarian vertically integrated generic pharmaceutical manufacturer, producing 653 products across 158 active ingredients and selling to pharmacies, physicians, and pharmaceutical partners in 100 countries under the Servier Group.
Ownership category
akta.pro rank

Egis Pharmaceuticals industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYCRAOAHAB
OTC Medicines & Consumer Health Products Distribution

Keywords

  • Generic pharmaceuticals
  • Active pharmaceutical ingredients
  • Pharmaceutical contract manufacturing
  • Finished dosage forms
  • Over-the-counter medicines

Where Egis Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Budapest
HQ country
Hungary
HQ region
Europe

Offices4 records

Markets served

Egis Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Generic Pharmaceutical Products: Sale of generic pharmaceutical products manufactured in-house. Portfolio of 653 products across 177 product families from 158 active ingredients. Products include cardiovascular, CNS, and other therapeutic categories sold in 100 countries.
  2. Contract Manufacturing Services: API contract development and manufacturing services offered to pharmaceutical partners. Services include process development, scale-up, and commercial API production under cGMP. Started in 2023.
  3. Licensing Activities: Licensing of pharmaceutical products and technologies to partners in various markets.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Egis Pharmaceuticals product offering

Product offering

Core offering

Egis manufactures and distributes generic pharmaceutical products including active pharmaceutical ingredients (APIs) and finished dosage forms — tablets, injections, and galenic preparations (ointments, suppositories, solutions, syrups) — across cardiovascular, CNS, diabetes, dermatology, gastroenterology, oncology, and women's health therapeutic areas, as well as a portfolio of OTC consumer health products. The company operates the full pharmaceutical value chain from API development and manufacturing through finished product manufacturing, packaging, sales, marketing, and licensing, supported by FDA-, EDQM-, PMDA-, KFDA-, and ANVISA-accredited cGMP facilities.

Product overview

Egis Pharmaceuticals is a pharmaceutical company with a comprehensive portfolio spanning active pharmaceutical ingredients (APIs) and finished dosage forms including tablets, injections, and galenic preparations (ointments, suppositories, solutions, syrups). The company manufactures 653 products organized into 177 product families derived from 158 different active ingredients, distributed to over 100 countries. Key therapeutic areas include cardiovascular (heart and vascular) and central nervous system, supplemented by diabetes, dermatology, and wound care. Egis also operates three Hungarian manufacturing sites (Budapest Keresztúri út for API production, Budapest Bökényföldi út for injectables and packaging, and Körmend for tablets and galenic products) and offers contract development and manufacturing services for pharmaceutical partners, including active ingredient development and manufacturing for both traditional and highly potent compounds.

Differentiator

Problem solved

Functional benefit

Brands

  • Egis Pharma Services: Contract manufacturing and contract development services for active pharmaceutical ingredients offered to pharmaceutical partners.

Products and services

  • Pharmaceutical Products Portfolio Core portfolio of 653 generic pharmaceutical products across 177 product families derived from 158 active ingredients, including APIs and finished dosage forms (tablets, injections, galenic preparations such as ointments, suppositories, solutions, syrups), distributed to 100 countries. Intended for healthcare professionals, pharmacies, and patients in cardiovascular, CNS, diabetes, dermatology, gastroenterology, oncology, and women's health therapeutic areas.
  • Cardiovascular Pharmaceuticals Generic prescription pharmaceutical products for the cardiovascular therapeutic area (heart and vascular diseases), one of Egis's two primary focus areas in Hungary. Sold through pharmacies and via field sales representatives to physicians and pharmacists.
  • Central Nervous System Pharmaceuticals Generic prescription pharmaceutical products for central nervous system disorders (neurological and psychiatric conditions), one of Egis's two primary focus areas in Hungary. Sold through pharmacies and via field sales representatives.
  • Crila (OTC anti-diarrhea) Over-the-counter anti-diarrhea product available without prescription through Hungarian pharmacies.
  • Reparon (OTC hemorrhoid treatment) Over-the-counter hemorrhoid treatment available without prescription through Hungarian pharmacies.
  • Betadine (OTC skin disinfection) Over-the-counter skin disinfection product available through Hungarian pharmacies.
  • Telviran (OTC herpes treatment) Over-the-counter herpes treatment available through Hungarian pharmacies.
  • Ambroxol Egis (OTC respiratory) Over-the-counter respiratory medication for acute and chronic respiratory conditions with mucus secretion, available through Hungarian pharmacies.
  • Paxirasol (OTC respiratory) Over-the-counter respiratory product for cough, asthma, and bronchitis to help clear airways, available through Hungarian pharmacies.
  • Egis Pharma Services Contract development and manufacturing services (CDMO) for active pharmaceutical ingredients (APIs) offered to pharmaceutical partners globally under cGMP, covering route scouting, synthesis development, scale-up, and commercial API production including highly potent compounds. Brand sub-brand of Egis.
  • Active Ingredient Contract Development Contract development services for active pharmaceutical ingredients including both traditional and highly potent (HP) compounds, with Budapest facilities featuring isolators for safe handling under cGMP.
  • Active Ingredient Contract Manufacturing Contract manufacturing of intermediates and active pharmaceutical ingredients using organic chemical synthesis with GMP-compliant processes at Budapest facilities, with reactor capacity from 630 L to 10,000 L.
  • HP Drug Substance Development and Manufacturing Highly potent drug substance development and GMP manufacturing with OEL levels between 1-10 micrograms (OEB4), including synthesis development, scale-up, and isolated production; dedicated production line capacity ~600 kg/year.
  • Chemical Manufacturing Services Large-scale chemical synthesis manufacturing services including aminolysis, Grignard reactions, nitration, hydrogenation, Friedel-Crafts reactions, and other specialized organic chemistry processes performed under cGMP.

Quantifiable outcome

  • Products reach 100 countries globally
  • +3 more outcomes

Companies that use Egis Pharmaceuticals

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Egis Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Egis Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Pharmaceutical Industry Partners (unspecified)coreStrategic or Co-development Partner · 1 January 2023Pharmaceutical partners for whom Egis provides contract development and manufacturing services for active pharmaceutical ingredients. Services include route scouting, synthesis development, scale-up, and commercial API production under cGMP conditions.
  • Regulatory Authorities (FDA, EDQM, PMDA, KFDA, ANVISA)coreOthersAccreditation and audit relationships with major regulatory authorities worldwide. Successfully passed comprehensive audits and received accreditation from FDA (USA, first in 1976), EDQM (EU), PMDA (Japan), KFDA (South Korea), ANVISA (Brazil).
  • Healthcare Professionals and Healthcare OrganizationscoreChannel Partner/ Reseller/ DistributorEgis engages with healthcare professionals (physicians, pharmacists) for product promotion, clinical collaboration, and transparency reporting under EFPIA Transparency Code. Healthcare organizations receive support and attend company-organized events.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Egis Pharmaceuticals competitors and assessment

Company assessment

Emerging players

  • Alvotech: Iceland-based biosimilar-focused manufacturer with vertically integrated development and manufacturing capabilities. Comparable to Egis's higher-end API capabilities (HP, isolator, advanced chemistry) and as a potential adjacent competitor for sophisticated contract manufacturing opportunities.

Direct peers

  • Recipharm: European CDMO offering contract development and manufacturing of APIs and finished dosage forms. Comparable to Egis's newly launched Egis Pharma Services API CDMO business, competing for the same pharmaceutical partner customers.
  • Stada Arzneimittel: German-headquartered European generics and consumer healthcare company with broad portfolio across cardiovascular, CNS, and OTC categories. Comparable to Egis as a European-focused, vertically organized generic and OTC manufacturer with multi-country distribution.
  • KRKA: Slovenian generic pharmaceutical manufacturer with strong CEE/CIS distribution, vertically integrated API production, and broad therapeutic coverage. Highly comparable to Egis in scale, footprint, and generics-led business model.
  • Polpharma: Polish pharmaceutical manufacturer and one of the largest CEE generic producers, with vertically integrated API and finished product manufacturing. Comparable to Egis on regional scale, therapeutic breadth, and integrated generics model.
  • Gedeon Richter: Hungarian-headquartered pharmaceutical company with vertically integrated generic and specialty pharma operations across CEE and Western Europe. Closely comparable to Egis on geography, therapeutic focus (CNS, cardiovascular, women's health), and integrated API-to-finished-product model.
  • Zentiva: Czech-headquartered European generic pharmaceutical company (formerly Sanofi generics) with strong CEE presence and broad finished-product portfolio. Comparable to Egis in CEE-centric generics focus and finished dosage-form manufacturing.

Broad incumbents

  • Sandoz: Novartis's standalone generics and biosimilars division with European heritage and broad API and finished product operations. Comparable to Egis on European generics distribution and biosimilar/specialty optionality, though at materially larger scale.
  • Hikma Pharmaceuticals: Multinational generic and specialty pharmaceutical manufacturer with strong MENA, US, and Europe presence. Comparable to Egis on vertically integrated generic manufacturing and broad geographic distribution, though with greater US exposure.
  • Teva Pharmaceutical Industries: Global generics and specialty pharma leader with extensive API and finished product operations. Comparable to Egis as a broader incumbent offering overlapping generic categories and contract manufacturing services, but at much larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Egis Pharmaceuticals social profiles

Digital presence

Egis Pharmaceuticals compliance and trust

Trust signal

Compliance14 records

Egis Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Egis Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Egis Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Egis Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Egis Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egis Pharmaceuticals

What does Egis Pharmaceuticals do?

Egis manufactures and distributes generic pharmaceutical products including active pharmaceutical ingredients (APIs) and finished dosage forms — tablets, injections, and galenic preparations (ointments, suppositories, solutions, syrups) — across cardiovascular, CNS, diabetes, dermatology, gastroenterology, oncology, and women's health therapeutic areas, as well as a portfolio of OTC consumer health products. The company operates the full pharmaceutical value chain from API development and manufacturing through finished product manufacturing, packaging, sales, marketing, and licensing, supported by FDA-, EDQM-, PMDA-, KFDA-, and ANVISA-accredited cGMP facilities.

Is Egis Pharmaceuticals a public or private company?

Egis Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.

When was Egis Pharmaceuticals founded?

Egis Pharmaceuticals was founded in 1913. It employs 1,001 to 5,000 people.

Where is Egis Pharmaceuticals based?

Egis Pharmaceuticals is headquartered in Budapest, Hungary, in the Europe region.

How does Egis Pharmaceuticals make money?

Three revenue lines are on record. Generic Pharmaceutical Products are the primary driver. The others are contract Manufacturing Services and licensing Activities.

Who are Egis Pharmaceuticals's main competitors?

Alvotech is listed as an emerging player. Direct peers are Recipharm, Stada Arzneimittel, KRKA, Polpharma, Gedeon Richter and Zentiva. Broad incumbents are Sandoz, Hikma Pharmaceuticals and Teva Pharmaceutical Industries.

Does Egis Pharmaceuticals have an API?

No public API is recorded for Egis Pharmaceuticals.

What industry is Egis Pharmaceuticals in?

Egis Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAO, Compounding Ingredient & API Distributors (Pharma Supply), with a secondary code of CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
UzdailyUzbekistan and Hungary's EGIS discuss pharmaceutical cooperationUzbekistan's medical and pharmaceutical industry agency met EGIS representatives on 18 November 2026 to discuss expanding pharmaceutical cooperation, including investment and new projects in Uzbekistan. EGIS, a Central and Eastern European manufacturer, reported 773.3 million euros in sales for 2024/2025 and allocated 56.6 million euros to R&D.BioSpaceHemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run CompletedHemogenyx Pharmaceuticals completed its second process qualification run for manufacturing HEMO-CAR-T cells in cGMP clean rooms, followed by analytical release tests. This run is the second of three required for an FDA IND application to start Phase I trials.BioSpaceRVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product SalesRVL Pharmaceuticals reported preliminary Q3 2022 UPNEEQ net product sales of approximately $10.0 million, a 19% increase over Q2 2022. The company also reported orders from about 3,500 cumulative unique medical aesthetics practices and revised Q4 2022 guidance to $12-14 million, representing 20-40% sequential growth.BioSpaceHemogenyx Pharmaceuticals PLC Announces Approval and Issuance of Antibody PatentHemogenyx Pharmaceuticals announced that China's National Intellectual Property Administration granted a patent on its bi-specific antibody method for conditioning patients for bone marrow transplantation. The patent, issued July 20, 2022, covers the method and related antibody compositions, aiming to replace toxic chemotherapy protocols.BioSpaceHemogenyx Pharmaceuticals PLC Announces Investor Webinar RecordingHemogenyx Pharmaceuticals announced that a recording of its investor webinar held on 6 July 2022 is now available on its YouTube channel. The company is a pre-clinical biopharmaceutical group developing treatments for blood and autoimmune diseases, including bone marrow transplantation. The webinar was presented by CEO Dr Vladislav Sandler.BioSpaceHemogenyx Pharmaceuticals PLC Announces Investor WebinarHemogenyx Pharmaceuticals announced a live investor webinar on 6 July 2022 at 16:00 BST, hosted by CEO Dr Vladislav Sandler. The webinar will cover the company's activities and future directions, with questions accepted by 1 July. The company is a pre-clinical biopharmaceutical group developing treatments for blood and autoimmune diseases.BenzingaRVL Pharmaceuticals plc - Ordinary Shares's Return On Capital Employed InsightsRVL Pharmaceuticals reported Q4 sales of $2.86 million and a loss of $19.72 million, a 10.43% decline from the prior quarter. The company's return on capital employed fell to -0.26%, indicating poor capital allocation. Q4 earnings per share of -$0.30 missed analyst estimates of -$0.27.BioSpaceCrescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®Crescita Therapeutics signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals for Pliaglis in eight Central and Eastern European countries. Crescita will receive an upfront payment of €0.65M (CAD$0.94M) and is eligible for cumulative sales and regulatory milestone payments. Egis expects to launch Pliaglis in Poland in early 2023.Business Wire BlogCrescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®Crescita Therapeutics signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals for Pliaglis in eight countries in Central and Eastern Europe. Crescita will receive an upfront payment of €0.65M (CAD$0.94M) and is eligible for cumulative sales and regulatory milestone payments. Egis expects to launch Pliaglis in Poland in early 2023.